Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04382573
Other study ID # RECHMPL20_0279
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date December 30, 2020

Study information

Verified date May 2020
Source University Hospital, Montpellier
Contact David GENEVIEVE, MH PD
Phone 04 67 33 61 04
Email d-genevieve@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

CDK13 related disorder is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and malformation syndrome.

The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile, and the brain MRI characteristics; and, second, to study the epigenetic signatures in a cohort of individuals with CDK13 intragenic pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.

Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment.

The investigators will be also happy to have either CD-ROM or a link to have access to the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.

Between 2019 and 2020, The investigators have already recruited data from individuals with CDK13 pathogenic variants from France and several European genetic centres.


Description:

The investigators aim to better understand and delineate the genetic syndrome CDK13 This genetic disorder was described in Sepember 2016 in Nature Genetics (PMID 27479907).

Since this first publication of 6 individuals carrying the pathogenic mutation CDK13, 37 other individuals carrying a pathogenic mutation of CDK13 have been reported in the litterature The investigators are seeking to better define the phenotype of individuals with pathogenic variants of CDK13, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, The investigators will gather clinical and neuropsychological data already carried out in the context of care.

The investigators also aim to gather the cerebral MRI scans already performed in order to better delimit the cerebral anomalies observed in individuals and if the sequence is adapted, The investigators will perform VBM studies.

Finally, The investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, The investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in CDK13 individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized CDK13 variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.

The expected benefits are a better understanding of CDK13 disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the CDK13 gene is pathological or not


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 30, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria:

- CDK13 intragenic pathogenic SNV (Single Nucleotide Variant)

Exclusion criteria:

- no pathogenic SNV in CDK13

- no consent for the study

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
Epigenetic signatures
Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)

Locations

Country Name City State
France UH Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of clinical data Clinical data such as growth parameters, facial, neurological, ENT, eye, cardiac, etc.. features 1 day
Primary Neuropsychological test Neuropsychological test with total IQ and subscore data using WISC or WAIS test 1 day
Secondary Evolution of genetic data Evolution of genetic data : Epigenetic signatures 1 day
See also
  Status Clinical Trial Phase
Completed NCT01671566 - Interval Training in Adults With Congenital Heart Disease a Randomized Trial N/A
Recruiting NCT01421030 - Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques Phase 0
Completed NCT01567579 - An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease
Withdrawn NCT00981591 - Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients Phase 1/Phase 2
Terminated NCT00208676 - Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease N/A
Completed NCT01941576 - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot N/A
Completed NCT01475357 - Intestinal Function in Neonates With Complex Congenital Heart Disease N/A
Active, not recruiting NCT01227096 - Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery N/A
Completed NCT01201486 - Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester N/A
Completed NCT00397514 - Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery N/A
Completed NCT02232399 - Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease? Phase 2
Completed NCT05191654 - Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD
Recruiting NCT06267859 - Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children Early Phase 1
Completed NCT02320669 - Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass Phase 3
Completed NCT01489475 - Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass N/A
Withdrawn NCT00579358 - Molecular Basis of Congenital Heart Defects
Recruiting NCT01196182 - Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
Recruiting NCT03822442 - MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
Completed NCT00450684 - Cardiac Resynchronization Therapy in Congenital Heart Defects Phase 2/Phase 3
Terminated NCT00208754 - Heart Failure in Adult Patients With a History of Congenital Heart Disease N/A